{
    "nctId": "NCT01410890",
    "officialTitle": "A Phase 3/4 Prospective Study to Characterize the Pharmacokinetics of Alglucosidase Alfa in Patients With Pompe Disease",
    "inclusionCriteria": "A participant was to meet all of the following criteria to be eligible for this study:\n\n* The participant and/or the participant's parent/legal guardian was willing and able to provide signed informed consent.\n* The participant had a confirmed acid alpha-glucosidase (GAA) enzyme deficiency from skin, blood, or muscle tissue and/or 2 confirmed GAA gene mutations.\n* Infant and toddler Pompe disease participants could be included in the study only under condition (minimal body weight) that the trial-related blood loss (including any losses in the maneuver) would not exceed 3 percent (%) of the total blood volume during a period of 4 weeks and would not exceed 1 % at any single time.\n* The participant, if female and of childbearing potential, must have had a negative pregnancy test (urine beta-human chorionic gonadotropin) at screening. Note: All female participants of childbearing potential and sexually mature males must have agreed to use a medically accepted method of contraception throughout the study.\n* For participants previously treated with alglucosidase alfa the participant had received alglucosidase alfa for at least 6 months.",
    "exclusionCriteria": "A participant who met any of the following criteria was excluded from this study:\n\n* The participant was participating in another clinical study using an investigational product.\n* The participant, in the opinion of the Investigator, was unable to adhere to the requirements of the study.\n\nThe above information was not intended to contain all considerations relevant to a participant's potential participation in a clinical trial."
}